.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
AstraZeneca
Daiichi Sankyo
Medtronic
Farmers Insurance
Cipla
Julphar
Harvard Business School
Federal Trade Commission
US Department of Justice

Generated: June 26, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204251

« Back to Dashboard
NDA 204251 describes SIMBRINZA, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the SIMBRINZA profile page.

The generic ingredient in SIMBRINZA is brimonidine tartrate; brinzolamide. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the brimonidine tartrate; brinzolamide profile page.

Summary for NDA: 204251

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1

Pharmacology for NDA: 204251

Suppliers and Packaging for NDA: 204251

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SIMBRINZA
brimonidine tartrate; brinzolamide
SUSPENSION/DROPS;OPHTHALMIC 204251 NDA Alcon Laboratories, Inc. 0065-4147 0065-4147-25 1 BOTTLE, DROPPER in 1 CARTON (0065-4147-25) > 2.5 mL in 1 BOTTLE, DROPPER
SIMBRINZA
brimonidine tartrate; brinzolamide
SUSPENSION/DROPS;OPHTHALMIC 204251 NDA Alcon Laboratories, Inc. 0065-4147 0065-4147-27 1 BOTTLE, DROPPER in 1 CARTON (0065-4147-27) > 8 mL in 1 BOTTLE, DROPPER

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION/DROPS;OPHTHALMICStrength0.2%;1%
Approval Date:Apr 19, 2013TE:RLD:Yes
Patent:9,044,484Patent Expiration:Oct 30, 2030Product Flag?YSubstance Flag?Delist Request?
Patent:9,421,265Patent Expiration:Jun 17, 2030Product Flag?YSubstance Flag?Delist Request?
Patent:6,316,441Patent Expiration:Dec 7, 2019Product Flag?Substance Flag?Delist Request?
Patented Use:REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATEINTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Chubb
Cantor Fitzgerald
Citi
QuintilesIMS
Medtronic
Queensland Health
Cipla
Accenture
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot